Comparative genomic analysis of oral versus laryngeal and pharyngeal cancer

Journal Article (2018)
Author(s)

David M. Vossen (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)

Caroline V.M. Verhagen (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)

Marcel Verheij (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)

Lodewyk F.A. Wessels (TU Delft - Electrical Engineering, Mathematics and Computer Science, Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)

Conchita Vens (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)

Michiel W.M. van den Brekel (Amsterdam UMC, Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis, Universiteit van Amsterdam)

Research Group
Pattern Recognition and Bioinformatics
DOI related publication
https://doi.org/10.1016/j.oraloncology.2018.04.006 Final published version
More Info
expand_more
Publication Year
2018
Language
English
Research Group
Pattern Recognition and Bioinformatics
Volume number
81
Pages (from-to)
35-44
Downloads counter
191

Abstract

Objective: Locally advanced oral squamous cell carcinoma (OSCC) shows lower locoregional control and disease specific survival rates than laryngeal and pharyngeal squamous cell carcinoma (L/P-SCC) after definitive chemoradiotherapy treatment. Despite clinical factors, this can point towards a different tumor biology that could impact chemoradiotherapy response rates. This prompted us to compare the mutational profiles of OSCC with L/P-SCC. Methods: We performed target capture DNA sequencing on 111 HPV-negative HNSCC samples (NKI dataset), 55 oral and 56 laryngeal/pharyngeal, and identified somatic point mutations and copy number aberrations. We next expanded our analysis with 276 OSCC and 134 L/P-SCC sample data from The Cancer Genome Atlas (TCGA dataset). We focused our analyses on genes that are frequently mutated in HNSCC. Results: The mutational profiles of OSCC and L/P-SCC showed many similarities. However, OSCC was significantly enriched for CASP8 (NKI: 15% vs 0%; TCGA: 17% vs 2%) and HRAS (TCGA: 10% vs 1%) mutations. LAMA2 (TCGA: 5% vs 19%) and NSD1 (TCGA: 7% vs 25%) mutations were enriched in L/P-SCC. Overall, we find that OSCC had fewer somatic point mutations and copy number aberrations than L/P-SCC. Interestingly, L/P-SCC scored higher in mutational and genomic scar signatures associated with homologous recombination DNA repair defects. Conclusion: Despite showing a similar mutational profile, our comparative genomic analysis revealed distinctive features in OSCC and L/P-SCC. Some of these genes and cellular processes are likely to affect the cellular response to radiation or cisplatin. Genomic characterizations may guide or enable personalized treatment in the future.